drugset / Trial / NCT01483963

AA4500 for the Treatment of Adhesive Capsulitis of the Shoulder

NCT01483963

Phase 2 Completed 50 enrolled Endo USA Inc., a Keenova Therapeutics Company
RandomizedParallel-groupOpen-labelTreatment

Summary

The objectives of this study are to assess the safety, effectiveness, and immunogenicity of AA4500 in the treatment of adhesive capsulitis.

Timeline

Start
2011-11
Primary completion
2013-02
Completion
2013-02

Drugs

EvaluationDrugModalityDoseRoute
Subject Collagenase Clostridium Histolyticum Protein / enzyme biologic 0.29 mg
Subject Collagenase Clostridium Histolyticum Protein / enzyme biologic 0.58 mg

Indications